Medifocus, Inc. to Make Clinical Presentation at 24th Annual National Interdisciplinary Breast Center Conference
12 3월 2014 - 10:10PM
Marketwired
Medifocus, Inc. to Make Clinical Presentation at 24th Annual
National Interdisciplinary Breast Center Conference
COLUMBIA, MD and TORONTO, ON--(Marketwired - Mar 12, 2014) -
Medifocus, Inc. (OTCQX: MDFZF) (TSX-VENTURE: MFS) is pleased to
announce that a clinical poster presentation of the Company's
breast cancer treatment system, the Microfocus APA 1000, will be
made at the 24th Annual National Interdisciplinary Breast Center
Conference, March 15-19, 2014 in Las Vegas, NV.
The poster presentation, "Wide-Field Focused Microwave
Thermotherapy in Combination with Neoadjuvant Anthracycline-Based
Chemotherapy to Increase Local Response for Improved Breast
Conservation Potential: Updated Phase III Clinical Trial Progress
Report" provides an update of the Company's Phase III randomized
study for patients with large breast cancer tumors. The
presentation will be held on Sunday, March 16th. The poster paper
is by the clinical investigators at the Company's two principal
sites in the United States (Dr. William C. Dooley, MD, University
of Oklahoma) and Canada (Dr. John R. Keyserlingk, MD, VM Medical
Center, the largest private breast center in Canada).
The Pivotal Phase III Breast Cancer treatment study has been
approved by both the US Food and Drug Administration and the
Canadian Bureau of Medical Devices (BMD). The goal of the 238
patient Medifocus-sponsored randomized Phase III study is to
demonstrate that preoperative focused microwave heat treatment and
chemotherapy combined are more effective than preoperative
chemotherapy alone in the treatment of large breast cancer tumors
in the intact breast. Combining heat with chemotherapy before
surgery can potentially shrink the tumor so that it can be removed
in a breast conserving surgery (lumpectomy), thus reducing the need
of a mastectomy.
Additional information on the conference can be found at
http://www2.breastcare.org/welcome-to-the-24th-annual-national-interdisciplinary-breast-center-conference/.
About Medifocus, Inc.
Medifocus owns two fully developed technology platforms with
comprehensive United States and international patent protection:
(i) The Endo-thermotherapy Platform-a catheter-basis focused heat
technology platform that utilizes natural body openings to deliver
precise microwave thermotherapy to the diseased sites. The United
States Food and Drugs Administration (FDA) approved Prolieve
Thermodilatation System for the treatment of Benign Prostatic
Hyperplasia (BPH) was developed based on the Endo-thermotherapy and
is currently generating revenue; and (ii) the Adaptive Phased Array
(APA) Microwave Focusing Platform, invented by the Massachusetts
Institute of Technology, licensed to Medifocus directs precisely
focused microwave energy at tumor center to induce shrinkage or
eradication of tumors without undue harm to surrounding tissue.
Medifocus' APA 1000 Breast Cancer Treatment System, developed from
the APA technology platform, has received approval from the FDA and
Health Canada to conduct the pivotal Phase III clinical trials.
Medifocus believes that these two technology platforms can provide
the design basis for the development of multiple cancer treatment
systems for surface, subsurface and deep seated localized and
regional cancers. Please visit www.medifocusinc.com,
www.prolieve.com and
http://www.facebook.com/pages/Medifocus-Inc-Company-Page/546315028715627
for more details.
Forward-Looking Statements and Information
This news release contains "forward-looking statements" and
"forward-looking information," which may not be based on historical
facts. Forward-looking statements and forward-looking information,
include, but are not limited to, information and statements with
respect the structure and the proceeds of the Offering and the
expected use of the proceeds. Forward-looking statements are
frequently characterized by words such as "plan," "expect,"
"project," "intend," "believe," "anticipate," "estimate" and other
similar words, or statements that certain events or conditions
"may" or "will" occur. Forward-looking statements are based on the
opinions and estimates of management at the date the statements are
made. Such forward-looking statements and forward-looking
information involve known and unknown risks, uncertainties and
other factors that may cause the actual results events or
developments to be materially different from any future results,
events or developments expressed or implied by such forward-looking
statements or forward-looking information. These factors should be
considered carefully and readers are cautioned not to place undue
reliance on such forward-looking statements and forward-looking
information. Except as required by applicable securities laws,
Medifocus disclaims any obligation to update any such factors or to
publicly announce the results of any revisions to any of the
forward-looking statements or forward-looking information contained
herein to reflect future results, events or developments.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Medifocus Contact: John Mon COO Medifocus, Inc. Tel:
410-290-5734 JohnMon@medifocusinc.com Investor Relations Contact:
Robert Giordano Consulting for Strategic Growth 1 T: 917-327-3938
rgiordanonyc@gmail.com
Medifocus (CE) (USOTC:MDFZF)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Medifocus (CE) (USOTC:MDFZF)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024